Press Releases
November 9, 2007 at 12:00 AM EST

Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting

CHESHIRE, Conn., Nov 09, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab) as a treatment for patients with PNH, have been published by the American Society of Hematology (ASH). Abstracts will be presented at the 2007 ASH annual meeting that is being held December 8 to 11, 2007 at the Georgia World Congress Center in Atlanta.

The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The abstracts and presentation information can be accessed at the links provided below.

     -- "High Incidence of Progression to Chronic Renal Insufficiency in
        Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)" Dr. Peter
        Hillmen et al.
        http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5416

     -- "Sustained Improvements in Transfusion Requirements, Fatigue and
        Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal
        Hemoglobinuria" Dr. Gerard Socie et al.
        http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5204

     -- "Disease.Related Symptoms Reported across a Broad Population of
        Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr. Gabrielle
        Meyers et al.
        http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5438.

The following abstract will be presented in an oral session on red cell regulation and disorders of production on Tuesday, December 11, 2007. The abstract and presentation information can be accessed at the link provided below.

     -- "Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria
        Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal
        Transfusion: Clinical Improvement with Eculizumab Therapy" Dr. Monica
        Bessler et al.
        http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5302.

    [ALXN-G]

SOURCE Alexion Pharmaceuticals, Inc.


 

 

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX